Loading patent…
AssigneeAsilomar Pharmaceuticals, Inc.
InventorsGordon Craig Hill, Stephen B. Kahl, Robert R. Webb, Constance A. McKee
Estimating the term…
A method for improving intracellular administration of a therapeutic agent is provided comprising: contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the cell transport the compound into the cell where the cell metabolizes at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.
A conjugated 1,4-pregnadiene-21-hydroxy steroid wherein a conjugate group pends from a steroid 21 hydroxyl group, and wherein the conjugate group comprises a nerve growth factor (NGF) or NGF receptor-binding fragment thereof.
A conjugated 4-pregnene-21-hydroxy-steroid wherein a conjugate group pends from a steroid 21 hydroxyl group, and wherein the conjugate group comprises a nerve growth factor (NGF) or NGF receptor-binding fragment thereof.
Dependencies are inferred from the claim text.